Pharmaceuticals
New Early Breast Cancer Drug Now Approved in Malaysia
SINGAPORE, July 16, 2020 /PRNewswire/ -- A NEW breast cancer drug shown to significantly reduce the risk of cancer recurrence is now approved for use in Malaysia. The drug, NERLYNX (neratinib), is an oral medication taken by women with breast cancer who have had surgery, chemotherapy and prior tr...
2020-07-17 06:16
2287
I-Mab Announces Authorization of Stock Repurchase Program up to $20 Million
SHANGHAI and GAITHERSBURG, Md., July 15, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its Board of Directors has authorized a stock repur...
2020-07-16 04:15
22173
Samsung Biologics and ImmuneOncia sign multi-product development and manufacturing agreement
SONGDO, South Korea, July 15, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics held a signing ceremony today for a contract to develop and manufacture five candidate molecules, expanding upon the two companies' existing CDO partnership first established in 2018. ...
2020-07-15 13:46
1833
Fosun Pharma Announces its Licensed COVID-19 Vaccine Product Receives Acceptance Notice of Clinical Trial Application by NMPA
SHANGHAI, July 14, 2020 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) announces that its subsidiary Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ("Fosun Pharmaceutical Industrial") has received the acceptance no...
2020-07-14 20:00
9912
Samsung Biologics signs additional development and manufacturing agreement with STCube
SONGDO, South Korea, July 11, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has further expanded its partnership with STCube through an additional development and manufacturing service agreement of STM418, an anti-PD1 immuno-oncology candidate. STM418 received much attention from the biopha...
2020-07-12 08:00
1786
Carromex Unveils Pharma Leads, a Groundbreaking Cloud-based Platform for Rapid Drug Analysis and Discovery
SYDNEY and MELBOURNE, Australia, July 9, 2020 /PRNewswire/ -- Carromex, a
mathematical research-based innovation company based inAustralia, unveiled a
new cloud-based pharmaceutical software platform called Pharma Leads
https://carromex.com/products/pharma-leads/
2020-07-10 11:31
1249
Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 to Treat Cervical Precancerous Lesions (HSIL)
SHANGHAI, July 8, 2020 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris), a China-based biotech company with global aspirations to discover, develop and commercialize innovative drugs for the treatment of genitourinary tumors and related diseases, announced today it has received Clinical Trial Ap...
2020-07-08 22:00
1357
ILIAS Biologics Granted Key Patent for Exosome-based Drug Delivery System in the United States
DAEJEON, South Korea, July 7, 2020 /PRNewswire/ -- ILIAS Biologics Inc. (the "Company" or "ILIAS"), a global leader in exosome-based therapeutics, announced today that the Company has been granted a key exosome engineering patent by the United States Patent and Trademark Office (USPTO). A patent...
2020-07-08 01:00
1348
Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions
SHANGHAI and PHILADELPHIA, July 1, 2020 /PRNewswire/ --Antengene Corporation today announced its appointment of Zhinuan Yu, Ph.D., as Corporate Vice President (CVP) of Biometrics and Regulatory Enabling Functions. Zhinuan will be responsible for providing statistical leadership and strategic r...
2020-07-02 08:16
1556
Transcenta Announces First Patient Dosed in Phase I Clinical Trial of Claudin18.2 Targeting Monoclonal Antibody TST001 in the US
SUZHOU, China, July 1, 2020 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced today that the first subject has been dosed successfull...
2020-07-01 23:00
1080
Coronavirus Breakthrough: New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19
TAIPEI and SAN DIEGO, July 1, 2020 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on Next Generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that its drug Silmitasertib was again identified as o...
2020-07-01 21:00
2783
'Curing Cancer without Surgery'
* "Successful disappearance of tumors in subjects upon administering the pain-free anticancer drug, Polytaxel, without side effects such as weight loss." * Suppressed 99.8% of tumors despite a non-toxic dose…more effective than existing FDA-approved pancreatic cancer drugs. * Hopes for a Kore...
2020-06-30 15:10
1506
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
MELBOURNE, Australia and SAN FRANCISCO, June 29, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH434 ...
2020-06-30 11:14
5979
China Biologic Provides Additional Comments on the Xinjiang Deyuan and Shuanglin Transaction
BEIJING, June 29, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today declared that the Company disagrees with the notice delivered by Xinjiang Deyuan Bioeng...
2020-06-29 13:00
11907
Mayne Pharma Announces FDA Filing Acceptance of New Drug Application for E4/DRSP in the US
ADELAIDE, Australia, June 24, 2020 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the New Drug Application (NDA) for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in ...
2020-06-24 12:10
5795
Kangpu to Present Two Posters at the 2020 American Association for Cancer Research (AACR) Annual Meeting
SHANGHAI, June 17, 2020 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company focused on the discovery and development of next-generation of immunomodulatory small molecules for the treatments of solid tumors, hematological malignancies, auto-immune diseases as well as inflammatory...
2020-06-17 21:00
1639
Immunexpress Awarded BARDA Contract to Develop SeptiCyte® RAPID for COVID-19 Patient Triage
SEATTLE, June 16, 2020 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, has been awarded a grant from the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary ...
2020-06-16 20:00
1041
Epredia and Lunaphore Announce Commercial Agreement for Exclusive Distribution of LabSat® Research
PORTSMOUTH, New Hampshire and LAUSANNE, Switzerland, June 15, 2020 /PRNewswire/
-- Epredia
2020-06-15 20:00
1653
I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program at the 2020 American Association for Cancer Research Virtual Meeting II
SHANGHAI and GAITHERSBURG, Md., June 12, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, will be presenting preclinical data on a newly developed, novel asset TJ...
2020-06-12 20:00
7083
PharmAbcine execute an agreement with Thermo Fisher for the development and manufacturing of its next-generation immune checkpoint blockade, PMC-309 for Phase I
DAEJEON, South Korea, June 10, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Thermo Fisher Scientific for the development and manufacturing of PMC-309, a next-generation immune checkpoint blockade to treat cancer. Under this agreement, PharmA...
2020-06-11 00:00
945
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 302 media titles]
2024-11-21 10:30Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8680
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5513
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
4990
Yingli Solar's Global Product Workshops Launched in Malaysia
2024-11-15 21:40
4738
